Do analysts prefer RSKD or ZSQR?

Riskified presently has a consensus target price of $6.43, suggesting a potential upside of 2.53%. Given Riskified's stronger consensus rating and higher probable upside, research analysts plainly believe Riskified is more favorable than Coeptis Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Riskified 2 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.13 Coeptis Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor RSKD or ZSQR?

In the previous week, Riskified had 22 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 26 mentions for Riskified and 4 mentions for Coeptis Therapeutics. Riskified's average media sentiment score of 0.38 beat Coeptis Therapeutics' score of -0.08 indicating that Riskified is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Riskified 9 Very Positive mention(s) 5 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral Coeptis Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts rate DJCO or ZSQR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Daily Journal Corp. (S.C.) 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Coeptis Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to DJCO or ZSQR?

In the previous week, Daily Journal Corp. (S.C.) had 4 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 8 mentions for Daily Journal Corp. (S.C.) and 4 mentions for Coeptis Therapeutics. Daily Journal Corp. (S.C.)'s average media sentiment score of 1.10 beat Coeptis Therapeutics' score of -0.08 indicating that Daily Journal Corp. (S.C.) is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Daily Journal Corp. (S.C.) 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Coeptis Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts recommend ZSQR or PAR?

PAR Technology has a consensus target price of $24.61, suggesting a potential upside of 31.47%. Given PAR Technology's stronger consensus rating and higher possible upside, analysts plainly believe PAR Technology is more favorable than Coeptis Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coeptis Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 PAR Technology 1 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.50

Does the media prefer ZSQR or PAR?

In the previous week, PAR Technology had 1 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 5 mentions for PAR Technology and 4 mentions for Coeptis Therapeutics. PAR Technology's average media sentiment score of 1.59 beat Coeptis Therapeutics' score of -0.08 indicating that PAR Technology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coeptis Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral PAR Technology 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor HIVE or ZSQR?

In the previous week, HIVE Digital Technologies had 14 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 18 mentions for HIVE Digital Technologies and 4 mentions for Coeptis Therapeutics. HIVE Digital Technologies' average media sentiment score of -0.06 beat Coeptis Therapeutics' score of -0.08 indicating that HIVE Digital Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HIVE Digital Technologies 4 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Coeptis Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts rate CGNT or ZSQR?

Cognyte Software presently has a consensus target price of $13.50, suggesting a potential upside of 50.33%. Given Cognyte Software's stronger consensus rating and higher possible upside, analysts clearly believe Cognyte Software is more favorable than Coeptis Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cognyte Software 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Coeptis Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor CGNT or ZSQR?

In the previous week, Coeptis Therapeutics had 1 more articles in the media than Cognyte Software. MarketBeat recorded 4 mentions for Coeptis Therapeutics and 3 mentions for Cognyte Software. Cognyte Software's average media sentiment score of 0.31 beat Coeptis Therapeutics' score of -0.08 indicating that Cognyte Software is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cognyte Software 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Coeptis Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Coeptis Therapeutics (ZSQR) Competitors

$3.92 -0.02 (-0.51%)

As of 03:21 PM Eastern

Compare

ZSQR vs. RSKD, DJCO, PAR, HIVE, and CGNT

Should you buy Coeptis Therapeutics stock or one of its competitors? Coeptis Therapeutics's main competitors and comparable companies include Riskified (RSKD), Daily Journal Corp. (S.C.) (DJCO), PAR Technology (PAR), HIVE Digital Technologies (HIVE), and Cognyte Software (CGNT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "application software" industry.

How does Coeptis Therapeutics compare to Riskified?

Riskified (NYSE:RSKD) and Coeptis Therapeutics (NASDAQ:ZSQR) are both small-cap technology companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends and profitability.

Coeptis Therapeutics has lower revenue, but higher earnings than Riskified. Riskified is trading at a lower price-to-earnings ratio than Coeptis Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Riskified	$344.64M	2.70	-$27.57M	-$0.11	N/A
Coeptis Therapeutics	N/A	N/A	-$11.92M	-$1.63	N/A

In the previous week, Riskified had 22 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 26 mentions for Riskified and 4 mentions for Coeptis Therapeutics. Riskified's average media sentiment score of 0.38 beat Coeptis Therapeutics' score of -0.08 indicating that Riskified is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Riskified	9 Very Positive mention(s)	5 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral
Coeptis Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Riskified presently has a consensus target price of $6.43, suggesting a potential upside of 2.53%. Given Riskified's stronger consensus rating and higher probable upside, research analysts plainly believe Riskified is more favorable than Coeptis Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Riskified	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

59.0% of Riskified shares are held by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are held by institutional investors. 17.4% of Riskified shares are held by insiders. Comparatively, 24.3% of Coeptis Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Riskified has a net margin of -4.23% compared to Coeptis Therapeutics' net margin of -773.72%. Riskified's return on equity of -3.93% beat Coeptis Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Riskified	-4.23%	-3.93%	-2.79%
Coeptis Therapeutics	-773.72%	-49.45%	-46.88%

Riskified has a beta of 1.38, meaning that its stock price is 38% more volatile than the broader market. Comparatively, Coeptis Therapeutics has a beta of -0.2, meaning that its stock price is 120% less volatile than the broader market.

Summary

Riskified beats Coeptis Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Coeptis Therapeutics compare to Daily Journal Corp. (S.C.)?

Daily Journal Corp. (S.C.) (NASDAQ:DJCO) and Coeptis Therapeutics (NASDAQ:ZSQR) are both small-cap technology companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, valuation, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Daily Journal Corp. (S.C.)	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Daily Journal Corp. (S.C.) has a net margin of -11.63% compared to Coeptis Therapeutics' net margin of -773.72%. Daily Journal Corp. (S.C.)'s return on equity of -3.11% beat Coeptis Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Daily Journal Corp. (S.C.)	-11.63%	-3.11%	-2.24%
Coeptis Therapeutics	-773.72%	-49.45%	-46.88%

In the previous week, Daily Journal Corp. (S.C.) had 4 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 8 mentions for Daily Journal Corp. (S.C.) and 4 mentions for Coeptis Therapeutics. Daily Journal Corp. (S.C.)'s average media sentiment score of 1.10 beat Coeptis Therapeutics' score of -0.08 indicating that Daily Journal Corp. (S.C.) is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Daily Journal Corp. (S.C.)	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Coeptis Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

51.2% of Daily Journal Corp. (S.C.) shares are held by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are held by institutional investors. 0.1% of Daily Journal Corp. (S.C.) shares are held by company insiders. Comparatively, 24.3% of Coeptis Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Daily Journal Corp. (S.C.) has higher revenue and earnings than Coeptis Therapeutics. Daily Journal Corp. (S.C.) is trading at a lower price-to-earnings ratio than Coeptis Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Daily Journal Corp. (S.C.)	$87.70M	9.54	$112.14M	-$8.22	N/A
Coeptis Therapeutics	N/A	N/A	-$11.92M	-$1.63	N/A

Daily Journal Corp. (S.C.) has a beta of 0.84, meaning that its stock price is 16% less volatile than the broader market. Comparatively, Coeptis Therapeutics has a beta of -0.2, meaning that its stock price is 120% less volatile than the broader market.

Summary

Daily Journal Corp. (S.C.) beats Coeptis Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Coeptis Therapeutics compare to PAR Technology?

Coeptis Therapeutics (NASDAQ:ZSQR) and PAR Technology (NYSE:PAR) are both small-cap technology companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

PAR Technology has a consensus target price of $24.61, suggesting a potential upside of 31.47%. Given PAR Technology's stronger consensus rating and higher possible upside, analysts plainly believe PAR Technology is more favorable than Coeptis Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
PAR Technology	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

13.9% of Coeptis Therapeutics shares are owned by institutional investors. 24.3% of Coeptis Therapeutics shares are owned by company insiders. Comparatively, 2.3% of PAR Technology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Coeptis Therapeutics has higher earnings, but lower revenue than PAR Technology. PAR Technology is trading at a lower price-to-earnings ratio than Coeptis Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coeptis Therapeutics	N/A	N/A	-$11.92M	-$1.63	N/A
PAR Technology	$455.55M	1.70	-$84.46M	-$1.76	N/A

PAR Technology has a net margin of -14.52% compared to Coeptis Therapeutics' net margin of -773.72%. PAR Technology's return on equity of -1.62% beat Coeptis Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coeptis Therapeutics	-773.72%	-49.45%	-46.88%
PAR Technology	-14.52%	-1.62%	-0.97%

In the previous week, PAR Technology had 1 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 5 mentions for PAR Technology and 4 mentions for Coeptis Therapeutics. PAR Technology's average media sentiment score of 1.59 beat Coeptis Therapeutics' score of -0.08 indicating that PAR Technology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Coeptis Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
PAR Technology	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Coeptis Therapeutics has a beta of -0.2, indicating that its share price is 120% less volatile than the broader market. Comparatively, PAR Technology has a beta of 1.33, indicating that its share price is 33% more volatile than the broader market.

Summary

PAR Technology beats Coeptis Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Coeptis Therapeutics compare to HIVE Digital Technologies?

HIVE Digital Technologies (NASDAQ:HIVE) and Coeptis Therapeutics (NASDAQ:ZSQR) are both small-cap technology companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, media sentiment, dividends, profitability, risk and institutional ownership.

24.4% of HIVE Digital Technologies shares are owned by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are owned by institutional investors. 24.3% of Coeptis Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

HIVE Digital Technologies has a net margin of -98.49% compared to Coeptis Therapeutics' net margin of -773.72%. HIVE Digital Technologies' return on equity of -29.90% beat Coeptis Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HIVE Digital Technologies	-98.49%	-29.90%	-26.19%
Coeptis Therapeutics	-773.72%	-49.45%	-46.88%

In the previous week, HIVE Digital Technologies had 14 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 18 mentions for HIVE Digital Technologies and 4 mentions for Coeptis Therapeutics. HIVE Digital Technologies' average media sentiment score of -0.06 beat Coeptis Therapeutics' score of -0.08 indicating that HIVE Digital Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HIVE Digital Technologies	4 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Coeptis Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

HIVE Digital Technologies has a beta of 3.79, meaning that its share price is 279% more volatile than the broader market. Comparatively, Coeptis Therapeutics has a beta of -0.2, meaning that its share price is 120% less volatile than the broader market.

HIVE Digital Technologies presently has a consensus target price of $6.95, indicating a potential upside of 125.80%. Given HIVE Digital Technologies' stronger consensus rating and higher possible upside, research analysts clearly believe HIVE Digital Technologies is more favorable than Coeptis Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HIVE Digital Technologies	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Coeptis Therapeutics has lower revenue, but higher earnings than HIVE Digital Technologies. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than HIVE Digital Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HIVE Digital Technologies	$297.79M	2.78	-$148.45M	-$1.29	N/A
Coeptis Therapeutics	N/A	N/A	-$11.92M	-$1.63	N/A

Summary

HIVE Digital Technologies beats Coeptis Therapeutics on 13 of the 15 factors compared between the two stocks.

How does Coeptis Therapeutics compare to Cognyte Software?

Cognyte Software (NASDAQ:CGNT) and Coeptis Therapeutics (NASDAQ:ZSQR) are both small-cap technology companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability.

Cognyte Software presently has a consensus target price of $13.50, suggesting a potential upside of 50.33%. Given Cognyte Software's stronger consensus rating and higher possible upside, analysts clearly believe Cognyte Software is more favorable than Coeptis Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cognyte Software	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

72.9% of Cognyte Software shares are held by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are held by institutional investors. 24.3% of Coeptis Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Cognyte Software has a beta of 1.67, meaning that its stock price is 67% more volatile than the broader market. Comparatively, Coeptis Therapeutics has a beta of -0.2, meaning that its stock price is 120% less volatile than the broader market.

In the previous week, Coeptis Therapeutics had 1 more articles in the media than Cognyte Software. MarketBeat recorded 4 mentions for Coeptis Therapeutics and 3 mentions for Cognyte Software. Cognyte Software's average media sentiment score of 0.31 beat Coeptis Therapeutics' score of -0.08 indicating that Cognyte Software is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cognyte Software	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Coeptis Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Cognyte Software has a net margin of -0.66% compared to Coeptis Therapeutics' net margin of -773.72%. Cognyte Software's return on equity of -0.45% beat Coeptis Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cognyte Software	-0.66%	-0.45%	-0.20%
Coeptis Therapeutics	-773.72%	-49.45%	-46.88%

Cognyte Software has higher revenue and earnings than Coeptis Therapeutics. Cognyte Software is trading at a lower price-to-earnings ratio than Coeptis Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cognyte Software	$400.04M	1.66	-$640K	-$0.04	N/A
Coeptis Therapeutics	N/A	N/A	-$11.92M	-$1.63	N/A

Summary

Cognyte Software beats Coeptis Therapeutics on 12 of the 15 factors compared between the two stocks.

Get Coeptis Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZSQR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZSQR vs. The Competition

Export

Metric	Coeptis Therapeutics	Software Industry	Technology Sector	NASDAQ Exchange
Market Cap	$201.61M	$15.39B	$30.43B	$13.03B
Dividend Yield	N/A	3.42%	2.72%	10.42%
P/E Ratio	-2.40	126.95	75.51	25.45
Price / Sales	N/A	1,305.66	600.77	98.02
Price / Cash	N/A	45.53	53.35	38.47
Price / Book	1.49	8.64	8.36	6.51
Net Income	-$11.92M	$435.62M	$679.85M	$347.22M
7 Day Performance	0.51%	-0.41%	1.33%	1.59%
1 Month Performance	-22.38%	2.77%	4.55%	2.79%
1 Year Performance	-71.94%	5.95%	200.66%	21.24%

Coeptis Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZSQR Coeptis Therapeutics	0.0639 of 5 stars	$3.92 -0.5%	N/A	-71.8%	$201.61M	N/A	N/A	2	Earnings Report
RSKD Riskified	2.11 of 5 stars	$6.31 +19.7%	$5.93 -6.0%	+24.2%	$780.76M	$344.64M	N/A	780	Earnings Report Insider Trade Gap Down High Trading Volume
DJCO Daily Journal Corp. (S.C.)	0.9823 of 5 stars	$557.01 -0.5%	N/A	+41.6%	$771.38M	$87.70M	54.88	320	Positive News Earnings Report
PAR PAR Technology	4.3962 of 5 stars	$17.95 +3.0%	$24.61 +37.1%	-63.6%	$720.95M	$455.55M	N/A	1,809	Positive News Gap Down
HIVE HIVE Digital Technologies	3.0692 of 5 stars	$2.74 +3.4%	$6.95 +153.8%	+21.2%	$711.87M	$297.79M	N/A	20	Trending News Earnings Report Analyst Forecast Options Volume Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZSQR) was last updated on 8/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Coeptis Therapeutics (ZSQR) Competitors

ZSQR vs. RSKD, DJCO, PAR, HIVE, and CGNT

How does Coeptis Therapeutics compare to Riskified?

Summary

How does Coeptis Therapeutics compare to Daily Journal Corp. (S.C.)?

Summary

How does Coeptis Therapeutics compare to PAR Technology?

Summary

How does Coeptis Therapeutics compare to HIVE Digital Technologies?

Summary

How does Coeptis Therapeutics compare to Cognyte Software?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZSQR vs. The Competition

Coeptis Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Coeptis Therapeutics (ZSQR) Competitors

ZSQR vs. RSKD, DJCO, PAR, HIVE, and CGNT

How does Coeptis Therapeutics compare to Riskified?

Which has stronger earnings and valuation, RSKD or ZSQR?

Does the media favor RSKD or ZSQR?

Do analysts prefer RSKD or ZSQR?

Do insiders and institutionals hold more shares of RSKD or ZSQR?

Is RSKD or ZSQR more profitable?

Which has more risk and volatility, RSKD or ZSQR?

Summary

How does Coeptis Therapeutics compare to Daily Journal Corp. (S.C.)?

Do analysts rate DJCO or ZSQR?

Is DJCO or ZSQR more profitable?

Does the media refer more to DJCO or ZSQR?

Do institutionals & insiders hold more shares of DJCO or ZSQR?

Which has preferable valuation & earnings, DJCO or ZSQR?

Which has more risk and volatility, DJCO or ZSQR?

Summary

How does Coeptis Therapeutics compare to PAR Technology?

Do analysts recommend ZSQR or PAR?

Do institutionals & insiders hold more shares of ZSQR or PAR?

Which has better valuation and earnings, ZSQR or PAR?

Is ZSQR or PAR more profitable?

Does the media prefer ZSQR or PAR?

Which has more volatility & risk, ZSQR or PAR?

Summary

How does Coeptis Therapeutics compare to HIVE Digital Technologies?

Do institutionals and insiders have more ownership in HIVE or ZSQR?

Is HIVE or ZSQR more profitable?

Does the media favor HIVE or ZSQR?

Which has more volatility & risk, HIVE or ZSQR?

Do analysts prefer HIVE or ZSQR?

Which has stronger valuation & earnings, HIVE or ZSQR?

Summary

How does Coeptis Therapeutics compare to Cognyte Software?

Do analysts rate CGNT or ZSQR?

Do institutionals & insiders believe in CGNT or ZSQR?

Which has more volatility and risk, CGNT or ZSQR?

Does the media favor CGNT or ZSQR?

Is CGNT or ZSQR more profitable?

Which has better valuation & earnings, CGNT or ZSQR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZSQR vs. The Competition

Coeptis Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools